AllDocs -> cancers

Fox Chase Cancer Center 2003 Scientific Report 1 Gastrointestinal Cancer Therapeutics. Meropol, Sigurdson, in collaboration with Allard, a Blanchard, § Cheng, § S. Cohen, § Eisenberg, § Engstrom, § Freedman, § Gallo, § Godwin, § Goldberg, § Hoffman, § Konski, § Lewis, § Rogatko, § Scott, § Szarka, § von Mehren, § Watson, § Weiner § Given the relative resistance of GI cancers to standard chemotherapeutic agents, a major emphasis of the GI cancer program at Fox Chase involves development of novel systemic approaches. Overall goals of the program are to: 1) develop treatments ...

General Practitioner in Oncology Self-directed Learning Program GASTROINTESTINAL CANCER MODULE Page 2 Anal Cancer Case Scenario 1 A 65-year-old woman presents to her family physician with a complaint of bleeding from a hemorrhoid. On rectal examination, a 2 cm mass is detected. She is referred to a surgeon, and undergoes biopsy, which reveals a moderately differentiated squamous cell carcinoma. 1. What staging working would you order and why? 2. What are some of the risk factors for anal cancer ? 3. In what age group is anal cancer more common in men than women? 4. In what age group is anal cancer more common in women than men? The patient undergoes chest x-ray, CBC, electrolytes, liver function tests, and a CT scan of the abdomen and pelvis. Chest x-ray is normal. CBC, electrolytes, urea, Creatinine, ...

Email this link to a friend . U.S. residents, click here to download a printable version of the latest announcement. Outside the U.S., click here for printable version of the latest announcement. The following companies have provided unrestricted educational grants in support of this conference: FOUNDING PLATINUM 16 - 19 JUNE 2004 World Congress on Gastrointestinal Cancer Barcelona, Spain Chairs: Mario Dicato, MD Luxembourg Medical Center Luxembourg, Luxembourg Eric Van Cutsem, MD, PhD University Hospital Gasthuisberg Leuven, Belgium Click here to register for this program Thursday, April 22, 2004 CONTENTS · Scientific Committee · Faculty · Scientific Agenda · Continuing Medical Education ...

Cambridge-Munich Upper Gastrointestinal Cancer Workshop Trinity College Cambridge March 28 th to 30 th 2004 Preliminary Programme Sunday 28 th March Afternoon - Tour of colleges Evening - Trinity College Drinks reception Guest lecture: Molecular imaging Professor Kevin Brindle, Biochemistry Department, Cambridge Informal buffet supper Page 2 Monday 29 th March Introduction and aims of the workshop : Carlos Caldas and Heinz Hoefler Morning session 1 – Genetic susceptibility to upper GI cancers Caldas (Oncology, Cambridge) Hereditary diffuse gastric cancer Keller/Vogelsang (Pathology, Munich) Familial gastric cancer Pharoah (Oncology, Cambridge) Low penetrance susceptibility genes - Stomach Oesophageal Cancer ...

PRACTICAL GASTROENTEROLOGY • MARCH 2004 52 INTRODUCTION N umerous studies have been done to examine what role diet plays in protection against gastrointesti- nal cancers. In order to make the best suggestions for physicians and patients, a careful review of the data is provided. The area of diet and cancer prevention is evolving, and, at the current time, much of the data is epidemiological or from basic science animal models. Some of the data is from humans in retrospective for- mat, prospective cohorts, and a few randomized placebo controlled studies. In order to understand the evolution and how suggestions are being formed, it is essential to review all of the studies available as each type has value. This article provides a review of the best data available and makes suggestions based on the literature at hand in regards to nutrients, diet, and cancer ...

TNFerade TM Combined with Chemoradiation in Gastrointestinal Cancer : Phase I/II Studies in Unresectable Locally Advanced Pancreatic and Resectable Esophageal Cancer Neil Senzer, MD Scientific Director Mary Crowley Medical Research Center US Oncology, Dallas, TX On behalf of the TNFerade TM Investigators Page 2 What is TNFerade TM ? • TNFerade is a second-generation (E1-, partial E3-, and E4-deleted) adenovector carrying the transgene encoding for TNF- a • A radiation-inducible promoter (Egr-1) is incorporated in the construct to optimize spatial and temporal gene expression following ionizing radiation Page 3 Rationale of TNFerade and Radiation Therapy Transcriptional targeting using a radiation- inducible, radio-sensitizing ...

cancer COLORECTAL CANCER William Grady, MD Division of Gastroenterology Vanderbilt University Medical Center 137,000 new cases in U.S. each year Colorectal Cancer Prevalent: 56,600 deaths, 50% five year mortality Deadly : >95% survival when detected early Treatable: Screening is effective for prevention Preventable: Colon: Anatomy and Function FUNCTION •Storage •Water absorption ANATOMY HISTOLOGY Colon Cancer : Heredity vs. Environment Sporadic Cancer ~65-90% FJP/PJS <0.1% FAP <1% HNPCC 1-2% CFCC 10-30% Adapted from Burt, Gastro, 2000 ...

Web Immagini Gruppi Directory News Novità! Ricerca avanzata Preferenze Cerca nel Web Cerca solo le pagine in Inglese Spiacenti, nessun contenuto associato a questo URL Web La ricerca di - cache:vQNv61IlPDIJ:groups.eortc.be/radio/PANCREAS/form.pdf allintitle: gastrointestinal cancer filetype:pdf OR filetype:doc OR filetype:ppt OR filetype:xls OR filetype:rtf - non ha prodotto risultati in nessun documento. Suggerimenti: - Assicurarsi che tutte le parole siano state digitate correttamente. - Provare con parole chiave diverse. - Provare con parole chiave più generiche. - Provare con un numero minore di parole chiave. ...

SEPTEMBER 2003 | Hem/Onc today 24 GASTROINTESTINAL CANCER DRUGS IN THE PIPELINE Information for this chart was gathered from the Pharmaceutical Research and Manufacturers of America, corporate Web sites, meeting abstracts, and the databases of H EM /O NC T ODAY . The publisher or editors do not assume responsibility for any errors or omissions. Generic Product Company Indication Phase 572016 Not yet available GlaxoSmithKline Colorectal cancer Phase 2 ABT-510 Not yet available Abbott Laboratories Colorectal cancer Phase 2 planned ABX-EGF Not yet available Abgenix Renal cancer Phase 2 Adenoviral p53 (INGN 201) Not yet available Introgen Therapeutics Esophageal squamous cell carcinoma Phase 1/2 ALVAC-CEA/B7.1 Not yet available ...

TUMOR M2-PK IN THE DIAGNOSIS OF GASTROINTESTINAL CANCER B.K. NGOUMOU, J. RUPP, P.D. HARDT, H. SCHNELL-KRETSCHMER and H.-U. KLOER Third Medical Department, Justus-Liebig-University, Giessen, Germany Introduction: Tumor M2-PK is the dimeric isoform of the tetrameric glycolytic enzyme pyruvate kinase. It is strongly overexpressed in tumor cells due to their modified metabolic state. It can be quantified in EDTA plasma with a commercially available ELISA test kit. Recent reports indicate that Tumor M2-PK is a marker for renal cell carcinoma and lung cancer [1,2]. It has also been investigated in pancreatic cancer and gastric cancer with promising results [3]. This study was designed to evaluate the use of this marker in gastrointestinal cancer . Because elevation of tumor markers sometimes can be observed in inflammatory ...

Changes in Body Composition During Upper Gastrointestinal Cancer Surgery A. Aslani 1 , B.A. Cooper 2 , A. Sevette 3 , R.C. Smith 3 1 Department of Nuclear Medicine, Royal North Shore Hospital, Pacific Highway, St Leonards, NSW 2065, Australia. 2 Department of Renal Medicine, Royal North Shore Hospital, Pacific Highway, St Leonards, NSW 2065, Australia. 3 Department of Surgery, Royal North Shore Hospital, Pacific Highway, St Leonards, NSW 2065, Australia. Abstract Background: Changes in weight and body composition (BC) are expected after most major abdominal surgery. Excess fluid retention especially may result in major morbidity in the post- operative patients. Loss of weight, itself, has been generally addressed by administration of appropriate intervention procedures. However, the components of ...

March 2003, Vol. 32 No. 2 219 Peritoneal Carcinomatosis from GI Cancer —D G Jayne * Senior Lecturer & Honorary Consultant Surgeon Academic Surgical Unit St. James’s University Hospital & University of Leeds, UK (formerly Colorectal Fellow, Singapore General Hospital, Singapore) Address for Reprints: Dr David Jayne, Academic Surgical Unit, Level 8, Clinical Sciences Building, St. James’s University Hospital, Beckett Street, Leeds LS9 7TF, United Kingdom. E-mail: meddgj@leeds.ac.uk The Molecular Biology of Peritoneal Carcinomatosis from Gastrointestinal Cancer D G Jayne,* MBBCh, MD, FRCS Abstract Introduction: Peritoneal carcinomatosis is a frequent form of disease progression in gastrointestinal cancer , and all too often is a preterminal event with a median survival of only 6 months. Despite the introduction of aggressive surgical ...

cancer Evolution of Imprinted Tumor Susceptibility Genes RANDY L. JIRTLE. Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710 USA Genomic imprinting is an epigenetic form of gene regulation that results in parent-of-origin dependent expression. Imprinted genes are normally involved in embryonic growth and behavioral development, but they also can cause cancer when their expression in somatic cells is deregulated by genetic and/or epigenetic mutations (1). We have demonstrated that imprinting of the oncogene, insulin-like growth factor 2 (IGF2), and the tumor suppressor gene, mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), evolved approximately 150 million years ago in an ancestor common to marsupials and eutherian mammals (1-3). The phenomenon of imprinting therefore evolved in mammals with the advent of live birth. Although IGF2 is imprinted in all Therian mammals, ...

JOURNAL OF PATHOLOGY J. Pathol. 187 : 223–228 (1999) SYNTHESIS OF BASEMENT MEMBRANE BY GASTROINTESTINAL CANCER CELL LINES TAKUMI AKASHI 1 *, TIZUKO MIYAGI 1 , NOBORU ANDO 1 , YOSHIMI SUZUKI 1 , TETSUO NEMOTO 1 , YOSHINOBU EISHI 1 , KYOICHI NAKAMURA 1 , TAKUJI SHIRASAWA 2 , NATSUMI OSA 3 , NOBORU TANAKA 3 AND ROBERT E. BURGESON 4 1 Department of Pathology, Tokyo Medical and Dental University, Tokyo, Japan 2 Department of Molecular Pathology, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan 3 PCL Japan, Tokyo, Japan 4 Cutaneous Biology Center, Harvard Medical School, Charleston, MA, U.S.A. SUMMARY Gastrointestinal adenocarcinoma-derived ...

GASTROINTESTINAL CANCER Prof. Dr. M. Peeters Dept of Gastroenterology/Oncology University Hospital Ghent On this thirty-ninth annual meeting of the American Society of Clinical Oncology in Chicago, Illinois, 524 abstracts on Gastrointestinal Cancer (GI) were published in the abstract book. Approximately 170 GI cancer papers were, either orally or as poster, presented at the meeting itself. Not only was the quantity excellent. Also the quality was outstanding this year. Mature data from several large, randomized trials became available and were discussed. For example, convincing results on the role of novel agents in the treatment of metastatic colorectal cancer were presented. The conclusions will certainly influence our clinical practice in the near future. It was absolutely necessary to make a selection in the presented material for this paper. ...

Fox Chase Cancer Center 2002 Scientific Report Gastrointestinal Cancer Therapeutics. Meropol, Sigurdson, in collaboration with Cheng, § S. Cohen, § Eisenberg, § Engstrom, § Freedman, § Goldberg, § Hoffman, § Konski, § Lewis, § Scott, § Szarka, § von Mehren, § Weiner, § Allard, a Gallo, § Godwin, § Raftogianis, § Rogatko, § Watson § Given the relative resistance of GI cancers to standard chemotherapeutic agents, a major emphasis of the GI cancer program at Fox Chase involves development of novel systemic approaches. Overall goals of the program are to: 1) develop treatments with ...

Page 1 GASTROINTESTINAL CANCER ANTIGEN (CA-199) ENZYME IMMUNOASSAY TEST KIT C a t a l o g C a t a l o g N u m b e r : N u m b e r : GBE-1006 Intended Use Enzyme Immunoassay for the Quantitative Measurement of Gastrointestinal Cancer Antigen (CA -199) EIA in Human Serum Introduction A group of Sialosyl Lewis Antigen (SLA) defined as a mucin type of glycoprotein such as CA 19-9, CA 195, has come to be recognized as circulating cancer associated antigen for gastrointestinal cancer (GI tumor antigen). Malignancies of pancreas, stomach and colon express these markers in a significant number of such patients. The GI Tumor Antigen ELISA test will measure CA 19-9 like GI tumor antigen in sera. It provides an aid in the evaluation of symptomatic patients suspected of having pancreatic cancer or related diseases, ...

Anaheim, CA 92807 1-800-222-9880 1268 N. Lakeview Ave. TECO DIAGNOSTICS CA 19-9 ( MICROTITER ASSAY ) Enzyme Immunoassay for the Quantitative Determination of Gastrointestinal Cancer Antigen CA 19-9 in Human Serum F OR I N V ITRO D IAGNOSTIC U SE O NLY Store at 2 to 8 ° C. P ROPRIETARY AND C OMMON N AMES CA19-9 Enzyme Immunoassay I NTENDED U SE For the quantitative determination of the Cancer Antigen CA19-9 concentration in human serum. I NTRODUCTION A group of mucin type glycoprotein Sialosyl Lewis Antigens (SLA), such as CA19-9 and CA19-5, have come to be recognized as circulating ...

The Fourth Annual Conference on Gastrointestinal Cancer A Multidisciplinary Approach for the Clinician March 19-23, 2003 Yarrow Hotel * Park City, Utah Presented by the University of Utah School of Medicine with the Huntsman Cancer Institute Photo courtesy of the Park City Convention and Visitors Bureau The Fourth Annual Conference on Gastrointestinal Cancer University of Utah Conference Services University Guest House 110 South Fort Douglas Boulevard Salt Lake City, UT 84113-5036 SUPPORT __ This meeting has been supported in part by unrestricted educational grants from: P RINCIPAL S PONSORS Pentax Precision Instrument Corporation Janssen Pharmaceutica, Inc Pharmacin Oncology Sanofi-Synthelabo O THER S PONSORS AstraZeneca ...

cancer Wharton Department of Statistics Data Mining Bob Stine Department of Statistics www-stat.wharton.upenn.edu/~bob Wharton Department of Statistics 2 Overview Applications Marketing: Direct mail advertising (Zahavi example) Biomedical: finding predictive risk factors Financial: predicting returns and bankruptcy Role of management Setting goals Coordinating players Critical stages of modeling process Picking the model <-- My research interest Validation Wharton Department of Statistics 3 Predicting Health Risk Who is at risk for a disease? Costs False positive: treat a healthy person False negative: miss a person with the disease Example: detect osteoporosis without need for x-ray What sort of predictors, ...

GASTROINTESTINAL CANCER Prof. Dr. Eric Van Cutsem UZ Gasthuisberg, Leuven Key issues discussed in this year’s gastrointestinal cancer sessions of the American Society of Clinical Oncology (ASCO) meeting included the role of combination chemotherapy in metastatic colorectal, the regimens of fluoropyrimidines (bolus, infusional, oral) in combination chemotherapy in colorectal cancer , the role of novel agents in colorectal cancer , the activity of combination regimens with gemcitabine in pancreatic cancer and multimodality studies in oesophageal cancer . Metastatic colon cancer Results from new trials confirm the higher activity of combination chemotherapy compared to 5-FU/FA. • The US Intergroup study N9741 randomized patients with advanced colorectal cancer between the IFL regimen (bolus 5-FA/FA + irinotecan), the Folfox 4 regimen ...

Summer, 2002 GWCCS Cancer Support Group & Internet Resource Guide Page 1 www.gwccs.org Greater Washington Coalition for Cancer Survivors (202) 364-6422 Colorectal & Gastrointestinal Cancer Support Groups SPONSOR GROUP / DESCRIPTION DAY & TIME LOCATION CONTACT & PHONE STATE Anne Arundel Medical Center Colorectal Cancer Support Group 2 nd Tuesday 7:00 PM AAMC Sajak Pavilion - 2001 Medical Parkway Annapolis, MD (443) 481-5369 MD Colorectal Cancer Network (CCNet) SemiColon - Two groups; one for survivors and one for caregivers 2 nd and 4 th Thursday 7:30-8:30 PM Holy Cross Hospital Audi- torium Forest Glen Road Silver Spring, MD Priscilla Savary ...

Fox Chase Cancer Center 2001 Scientific Report Gastrointestinal Cancer Therapeutics. Meropol, Sigurdson, Cohen, in collaboration w i t h Cheng, § Eisenberg, § E n g s t r o m , § Freedman, § Goldberg, § Hoffman, § Lewis, § Scott, § Szarka, § von Mehren, § Weiner, § Allard, a Gallo, § Godwin, § Raftogianis, § Rogatko § Given the relative resistance of GI cancers to standard chemotherapeutic agents, a major emphasis of the GI cancer program at Fox Chase involves development of novel systemic approaches. Overall goals of the program are to: 1) develop treatments with improved target selectivity, and 2) identify tumor characteristics ...

cancer Wharton Department of Statistics Profiting from Data Mining Bob Stine Department of Statistics The Wharton School, Univ of Pennsylvania April 5, 2002 www-stat.wharton.upenn.edu/~bob Wharton Department of Statistics 2 Overview Critical stages of data mining process Choosing the right data, people, and problems Modeling Validation Automated modeling Feature creation and selection Exploiting expert knowledge, “insights” Applications Little detail – Biomedical: finding predictive risk factors More detail – Financial: predicting returns on the market Lots of detail – Credit: anticipating the onset of bankruptcy Wharton Department of Statistics 3 Predicting Health Risk Who is at risk for a disease? Example: detect osteoporosis ...

gastrointestinal cancer Laparoscopic Ultrasound in Upper Gastrointestinal Cancer Staging Jesper Durup,MD,PhD and Claus Hovendal,MD,PhD Dept of Surgical Gastroenterology, Odense University Hospital, Denmark Introduction: Besides having a correct diagnosis accurate pretherapeutic staging and assessment of resectability in upper gastrointestinal malignancies (UGIM) are important in order to group the patients for different treatment strategies. One of the most important clinical tasks is to identify the patients that cannot be operated. Unnecessary laparotomies in patients with non-resectable UGIM will increase mortality and morbidity as well as reduce the quality of life in their short remaining life time period. In this chapter we will discuss the use of Laparoscopic Ultrasound (LUS) regarding the pretherapeutic identification of non-resectable UGIM, and comment ...

1 8 2 Medical Science Division Gastrointestinal Cancer Therapeutics. Meropol, Sigurdson, Cohen, Cheng, § Eisenberg, § Engstrom, § Freedman, § Goldberg, § Hoffman, § Lewis, § Pinover, § Szarka, § v o n Mehren, § Weiner, § Cohen a Given the relative resistance of GI cancers to standard chemotherapeutic agents, a major e m p h a s i s o f t h e G I c a n c e r p ro g r a m a t Fox Chase involves development of novel sys- temic approaches. Clinical trials include thera- pies based upon molecular targets, as well as traditional cytotoxics with preclinical evidence of improved antitumor activity or selectivity. Pharmacologic modeling of new agents is rou- tinely performed (see ...

Abstract: Significant benefits have been gained with pre or peri-operative nutritional support in surgical patients with malnutrition. Recent studies have also shown that some enteral formulas including certain nutrients like glutamine could provide more benefit than the standard formulas. In this prospective-randomized study, the effects of perioperative oral supplement with enteral formulas containing glutamine in comparison with a standard enteral formula in patients who were operated on for GI malignancies were examined. Thirty-two patients were divided into two groups: the study group was given oral supplement with an elemental diet (Alitraq ® ) for 7 days preoperatively and 10 days postoperatively as 30-35% of total daily requirement (standard hospital diet: 65- 70%), while the control group received a polymeric formula (Ensure ® ) as the ...

1 8 0 Medical Science Division GASTROINTESTINAL CANCER PROGRAM Neal J. Meropol, M.D., Member, Director, Gastrointestinal Cancer Program, Director, Gastrointestinal Tumor Risk Assessment Program Elin R. Sigurdson, M.D., Ph.D., Member, Surgical Co-Director, Gastrointestinal Cancer Program Jonathan D. Cheng, M.D., Research Fellow (now Assistant Member, Medical Science) Alida Schleyer, R.N., B.S.N., Project Coordinator Sandy Corbett, B.S., Project Assistant Joni James,* M.P.H., Health Educator Susan Mazzoni, M.P.H., Health Educator Monica Davey, R.N., B.S.N., M.B.A., Clinical Research Coordinator Susan McLaughlin, R.N., Clinical Research Coordinator Mary Beard, B.A., C.T.R., Clinical Research Associate Carolyn Rosado, B.S., Clinical Research Associate ...

ANNUAL RESEARCH REPORT 1998 143 Gastrointestinal Cancer Unit Gastrointestinal Cancer Unit, RMT Sutton (in association with the ICR Section of Medicine) HOSPITAL-BASED CLINICAL RESEARCH Head of Unit D Cunningham MD FRCP T he GI Unit is one of the largest clinical units in the Trust seeing between 900 and 1000 new patients a year with gastro- intestinal malignancies. The Unit enters over 70% of patients into prospective clinical trials, many of which are multicentred UK trials coordinated by the MRC or UKCCCR. New drug development, in collaboration with the CRC Centre for Cancer Therapeutics, and metabolic imaging are also major components of the Unit’s work. We have coordinated the RASCAL group which has shown that the presence of mutations in K-ras conveys an increased risk of relapse following ...